AMA CPT® Assistant - 2021 Issue 6 (June)
Genetic Analyses for Myelodysplastic Syndrome and Acute Myeloid Leukemia (June 2021)
June 2021 pages 9-10 Genetic Analyses for Myelodysplastic Syndrome and Acute Myeloid Leukemia New codes were added to the Molecular Pathology subsection of the Pathology and Laboratory section of the Current Procedural Terminology (CPT®) 2021 code set, several of which were discussed in previous issues of CPT® Assistant. This article introduces four new additional Tier 1 codes (81347, 81348, 81357, 81360) that were added to report genetic analysis of genes linked to myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Tier 1 Molecular Pathology Procedures 81347SF3B1 (splicing factor [3b] subunit B1) (eg, myelodysplastic syndrome/acute myeloid leukemia) gene analysis...
Subscribe or sign in to view the full article.
Article Overview
This CPT® Assistant article explains a set of molecular pathology coding updates tied to genetic analysis in myelodysplastic syndrome and acute myeloid leukemia. It is relevant to pathology and laboratory coders, clinicians, and billing staff who work with molecular testing and CPT® code changes. The article presents the new code introductions in context and includes clinical examples with procedural descriptions that illustrate the covered testing scenarios.
Why This Topic Matters
It helps readers understand the scope of the 2021 CPT® changes for molecular testing in hematologic malignancies and identify when the article’s guidance applies.
Article Sections
-
Tier 1 Molecular Pathology Procedures
Introduces a small set of molecular pathology code updates within the CPT® 2021 code set and places them in the context of hematologic malignancy testing.
-
Clinical Examples and Description of Procedure
Provides representative patient scenarios and procedure summaries for the testing discussed in the article.
What You Will Learn
- Which molecular pathology topics are addressed in the CPT® 2021 update
- How the article frames genetic testing related to MDS and AML
- What kinds of clinical scenarios are illustrated in the examples
- How the article presents the relationship between the code updates and laboratory testing workflows
Who Should Read This
- Medical coders
- Pathology and laboratory professionals
- Billing staff
- Compliance teams
- Clinicians involved in hematology testing
Codes Discussed
Subscribe or sign in to view the full article.


Quick, Current, Complete - www.findacode.com